As Moderna maps out a more cautious future amid lower-than-expected sales of its current products, the company is bolstering ...

Moderna is the only company in its peer group burning cash at an alarming rate. Click here to read more about MRNA stock and ...

The mRNA treatment landscape is shaping up to be competitive, but the market is also nascent, with the covid pandemic marking the first commercial product from Moderna, the industry leader.

Delving into the details, we found 51% of traders were bullish, while 25% showed bearish tendencies. Out of all the trades we ...

With only one commercial product – the COVID-19 vaccine – Moderna faces pressure to diversify its pipeline rapidly. As the company invests heavily in expanding its non-COVID mRNA vaccine ...

The patent has also been contested by Sanofi, which was also developing an mRNA-based COVID-19 vaccine ... led to a traditional private commercial model. Moderna and Pfizer/BioNTech have both ...

Moderna wins EU tender to supply COVID-19 vaccines for up to four years, offering diverse formats like prefilled syringes to enhance healthcare delivery.

In this article, we are going to take a look at where Moderna, Inc. (NASDAQ:MRNA) stands among Wednesday’s worst-performing stocks. The stock market declined on Wednesday, with all major indices ...

US mRNA specialist Moderna demonstrated substantial R&D investment and progress in the UK, two years since signing its ...

In a report released yesterday, Courtney Breen from Bernstein maintained a Hold rating on Moderna (MRNA – Research Report), with a price target of $45.00. The company’s shares closed yesterday ...

Shares of Moderna (NASDAQ: MRNA) zoomed as much as 33.3% higher this week, according to data from S&P Global Market Intelligence. The maker of vaccines, including the mRNA vaccine for COVID-19 ...

Financial giants have made a conspicuous bullish move on Moderna. Our analysis of options history for Moderna (NASDAQ:MRNA) revealed 31 unusual trades. Delving into the details, we found 51% of ...